8-K: MariMed Reports Record Revenue for 2023, Expands Maryland Footprint

MariMed Inc. announced record revenue for 2023, driven by strong wholesale performance and new asset openings, while also expanding its presence in Maryland with a pending dispensary acquisition.

Summary

• MariMed reported its financial results for the fourth quarter and full year ended December 31, 2023, achieving record revenue of $148.6 million for the year, a significant increase from $134.0 million in 2022.
• The company experienced double-digit revenue growth for the sixth consecutive year and positive adjusted EBITDA for the fourth consecutive year.
• Full year GAAP gross margin was 44%, while non-GAAP gross margin was 45%.
• GAAP net loss was $16.0 million for the year, compared to a net income of $13.6 million in the previous year.
• Non-GAAP net loss was $0.8 million for the year, compared to a non-GAAP net income of $22.2 million in 2022.
• Non-GAAP adjusted EBITDA was $24.7 million for the year, down from $32.4 million in 2022.
• The company refinanced its debt for $58.7 million, lowering the weighted average cost of debt to 8% with a 10-year term and a fixed 8.4% interest rate for the first five years.
• MariMed is expanding its Maryland footprint with a pending acquisition of a dispensary in Upper Marlboro for $5.25 million.
• The company anticipates transitioning to a permanent facility for its Casey, Illinois dispensary in the first quarter of 2024.
• For 2024, MariMed projects revenue growth of 5% to 7%, non-GAAP adjusted EBITDA growth of 0% to 2%, and capital expenditures of $10 million.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth is positive, the decrease in profitability and adjusted EBITDA is concerning. The debt refinancing and expansion are positive developments, but the overall sentiment is neutral to slightly negative due to the reduced profitability.

Positives

• MariMed achieved record revenue in 2023, demonstrating strong growth.
• The company has consistently delivered positive adjusted EBITDA for four years.
• The debt refinancing significantly reduced the cost of debt and improved the company's financial position.
• The expansion into Maryland through acquisition will increase the company's market presence.
• The company's new processing facility in Illinois is now operational, contributing to wholesale revenue.
• The company has a conservative approach to financial targets for 2024, focusing on organic growth.

Negatives

• The company reported a GAAP net loss of $16.0 million for 2023, a significant decrease from the $13.6 million net income in 2022.
• Non-GAAP net loss was $0.8 million for the year, compared to a non-GAAP net income of $22.2 million in 2022.
• Non-GAAP adjusted EBITDA decreased to $24.7 million in 2023 from $32.4 million in 2022.
• The company's gross margin decreased from 48% in 2022 to 44% in 2023.

Risks

• The company's financial results are subject to risks and uncertainties, including changes in demand, regulatory changes, and economic conditions.
• The pending acquisition in Maryland is subject to regulatory approval, which could be delayed or denied.
• The company's 2024 financial targets do not include potential revenue from new projects, which could impact future growth.
• The company's non-GAAP financial measures may not be directly comparable to those of other companies.

Future Outlook

MariMed anticipates continued growth in 2024, projecting revenue growth of 5% to 7% and non-GAAP adjusted EBITDA growth of 0% to 2%. These targets are based on organic growth and do not include potential revenue from new projects.

Management Comments

• Jon Levine, Chief Executive Officer, stated that the company had a record year with respect to revenue generation, particularly in wholesale, new asset openings, and leveraging balance sheet strength to secure capital.
• Jon Levine believes MariMed stands alone among cannabis companies for the longevity of delivering strong financial results.
• Management anticipates continuing this track record as the commencement of wholesale operations in Illinois is contributing to a solid start in 2024.

Industry Context

The cannabis industry is experiencing growth, and MariMed's expansion and financial performance reflect this trend. The company's focus on wholesale and new asset openings aligns with industry strategies for growth. The debt refinancing is a positive move in a capital-intensive industry.

Comparison to Industry Standards

• MariMed's revenue growth of approximately 11% year-over-year is solid, but the decrease in profitability is a concern. Companies like Curaleaf and Trulieve have shown higher revenue growth and profitability in recent periods, though they are larger companies.
• The debt refinancing at 8% is a positive move, as many cannabis companies face higher borrowing costs. This is a better rate than some peers, such as Cresco Labs, which have faced higher interest rates on their debt.
• The acquisition of a dispensary in Maryland is a strategic move, as the state's cannabis market is growing. This is similar to moves by other multi-state operators to expand their footprint.
• MariMed's focus on organic growth for 2024 is a more conservative approach compared to some peers that are aggressively expanding through acquisitions. This may lead to slower growth but potentially more stable results.

Stakeholder Impact

• Shareholders may be concerned about the decrease in profitability, but the revenue growth and debt refinancing are positive.
• Employees may benefit from the company's expansion and growth.
• Customers will have access to more dispensaries and products as the company expands.
• Suppliers may see increased demand for their products as the company grows.
• Creditors may view the debt refinancing as a positive sign of the company's financial stability.

Next Steps

• MariMed will transition to its permanent dispensary facility in Casey, Illinois, during the first quarter of 2024.
• The company will seek regulatory approval for the acquisition of the dispensary in Upper Marlboro, Maryland.
• MariMed will continue to focus on organic growth and operational efficiency in 2024.

Key Dates

Keywords

cannabis, MariMed, financial results, revenue, EBITDA, dispensary, acquisition, debt refinancing, wholesale, Illinois, Maryland